These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33661366)

  • 1. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
    Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
    Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study.
    Tentoni N; Hwang M; Villanueva G; Combs R; Lowe J; Ramsey LB; Taylor ZL; Carrillo TM; Aumente MD; López-Viñau López T; Rizzari C; Howard SC
    Cancer Med; 2024 Sep; 13(17):e70176. PubMed ID: 39254047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
    O'Donoghue DF; Truong HL; Finnes HD; McDonald JS; May HP; Ansell SM; Bennani NN; Habermann TM; Inwards DJ; Johnston PB; Khurana A; Lin Y; Micallef IN; Nowakowski GS; Paludo J; Porrata LF; Thanarajasingam G; Thompson CA; Villasboas JC; Wang Y; Witzig TE; Leung N
    JCO Oncol Pract; 2022 Dec; 18(12):e1908-e1917. PubMed ID: 36240468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
    DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
    Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
    Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
    J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
    Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
    Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
    Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
    Dhingra H; Kalra M; Mahajan A
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
    Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
    Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
    Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing and Managing Toxicities of High-Dose Methotrexate.
    Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
    Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
    Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
    J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients.
    Peng C; Li X; Huang H; Liu T; Wang Z; Fang X; Hong H; Li F; Ren Q; Liu S; Tian Y; Lin T
    Leuk Lymphoma; 2020 Aug; 61(8):1842-1849. PubMed ID: 32316801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.